JP2020533334A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533334A5 JP2020533334A5 JP2020514257A JP2020514257A JP2020533334A5 JP 2020533334 A5 JP2020533334 A5 JP 2020533334A5 JP 2020514257 A JP2020514257 A JP 2020514257A JP 2020514257 A JP2020514257 A JP 2020514257A JP 2020533334 A5 JP2020533334 A5 JP 2020533334A5
- Authority
- JP
- Japan
- Prior art keywords
- rnai agent
- agent according
- nucleotides
- composition
- sense strand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023051640A JP2023073358A (ja) | 2017-09-11 | 2023-03-28 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
| JP2025285009A JP2026042849A (ja) | 2017-09-11 | 2025-12-26 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
| JP2025285010A JP2026042850A (ja) | 2017-09-11 | 2025-12-26 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762556818P | 2017-09-11 | 2017-09-11 | |
| US62/556,818 | 2017-09-11 | ||
| US201862643927P | 2018-03-16 | 2018-03-16 | |
| US62/643,927 | 2018-03-16 | ||
| US201862720434P | 2018-08-21 | 2018-08-21 | |
| US62/720,434 | 2018-08-21 | ||
| PCT/US2018/050248 WO2019051402A1 (en) | 2017-09-11 | 2018-09-10 | RNA INTERFERENCE AGENTS AND COMPOSITIONS FOR INHIBITING THE EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023051640A Division JP2023073358A (ja) | 2017-09-11 | 2023-03-28 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020533334A JP2020533334A (ja) | 2020-11-19 |
| JP2020533334A5 true JP2020533334A5 (enExample) | 2021-10-07 |
| JP7438103B2 JP7438103B2 (ja) | 2024-02-26 |
Family
ID=65630632
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020514257A Active JP7438103B2 (ja) | 2017-09-11 | 2018-09-10 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
| JP2023051640A Withdrawn JP2023073358A (ja) | 2017-09-11 | 2023-03-28 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
| JP2025285010A Pending JP2026042850A (ja) | 2017-09-11 | 2025-12-26 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
| JP2025285009A Pending JP2026042849A (ja) | 2017-09-11 | 2025-12-26 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023051640A Withdrawn JP2023073358A (ja) | 2017-09-11 | 2023-03-28 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
| JP2025285010A Pending JP2026042850A (ja) | 2017-09-11 | 2025-12-26 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
| JP2025285009A Pending JP2026042849A (ja) | 2017-09-11 | 2025-12-26 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US10597657B2 (enExample) |
| EP (1) | EP3681516A4 (enExample) |
| JP (4) | JP7438103B2 (enExample) |
| KR (2) | KR20240161202A (enExample) |
| CN (2) | CN118879696A (enExample) |
| AU (2) | AU2018329190B2 (enExample) |
| BR (1) | BR112020002413A2 (enExample) |
| CA (1) | CA3074303A1 (enExample) |
| CL (2) | CL2020000593A1 (enExample) |
| CO (1) | CO2020002586A2 (enExample) |
| CR (1) | CR20200108A (enExample) |
| EC (1) | ECSP20017905A (enExample) |
| IL (2) | IL273172B2 (enExample) |
| JO (1) | JOP20200054A1 (enExample) |
| MX (2) | MX2020002648A (enExample) |
| MY (1) | MY202025A (enExample) |
| PE (1) | PE20201283A1 (enExample) |
| PH (1) | PH12020500332A1 (enExample) |
| SG (1) | SG11201912178VA (enExample) |
| TN (1) | TN2020000039A1 (enExample) |
| TW (2) | TWI811238B (enExample) |
| UA (1) | UA130735C2 (enExample) |
| UY (1) | UY37871A (enExample) |
| WO (1) | WO2019051402A1 (enExample) |
| ZA (1) | ZA202100806B (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016081444A1 (en) | 2014-11-17 | 2016-05-26 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
| JOP20170056B1 (ar) * | 2016-09-02 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | مركبات ترابطية مستهدفة |
| US11015198B2 (en) | 2017-04-05 | 2021-05-25 | Silence Therapeutics Gmbh | Products and compositions |
| SG11201912178VA (en) * | 2017-09-11 | 2020-01-30 | Arrowhead Pharmaceuticals Inc | Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3) |
| CN118291456A (zh) | 2017-12-01 | 2024-07-05 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2019105414A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| HRP20250277T1 (hr) | 2017-12-01 | 2025-05-09 | Suzhou Ribo Life Science Co., Ltd. | Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba |
| JP7507495B2 (ja) * | 2018-12-28 | 2024-06-28 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| CN113227376B (zh) | 2019-05-22 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| JP7610848B2 (ja) | 2019-05-22 | 2025-01-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| CN113286888B (zh) | 2019-05-22 | 2023-12-22 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CN113795582B (zh) | 2019-05-24 | 2024-05-24 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| WO2021026150A1 (en) * | 2019-08-05 | 2021-02-11 | Arrowhead Pharmaceuticals, Inc. | Methods for the treatment of apoc3-related diseases and disorders |
| CN115397989A (zh) | 2020-02-18 | 2022-11-25 | 阿尔尼拉姆医药品有限公司 | 载脂蛋白C3(APOC3)iRNA组合物及其使用方法 |
| CN114480382A (zh) * | 2020-11-12 | 2022-05-13 | 北京大学 | 用于抑制SURF4基因表达的RNAi试剂和组合物 |
| CN116829717A (zh) * | 2021-01-30 | 2023-09-29 | e-生物有限公司 | 含有无碱基核苷酸的核酸 |
| EP4176061A1 (en) * | 2021-01-30 | 2023-05-10 | E-Therapeutics plc | Nucleic acids containing abasic nucleotides |
| BR112023014443A2 (pt) * | 2021-01-30 | 2024-01-23 | E Therapeutics Plc | Ácidos nucleicos contendo nucleotídeos abásicos |
| US12612626B2 (en) | 2021-06-24 | 2026-04-28 | Sirnaomics, Inc. | siRNA compound that inhibits expression of APOC3 |
| CN117580953B (zh) * | 2021-07-16 | 2025-07-18 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CA3232053A1 (en) * | 2021-10-08 | 2023-04-13 | E-Therapeutics Plc | Nucleic acids containing abasic nucleosides |
| KR20240103025A9 (ko) | 2021-11-16 | 2025-12-10 | 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. | 안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법 |
| JP7877458B2 (ja) | 2021-12-01 | 2026-06-22 | ディセルナ ファーマシューティカルズ インコーポレイテッド | Ａｐｏｃ３発現を調節するための組成物及び方法 |
| TW202340469A (zh) * | 2022-01-20 | 2023-10-16 | 大陸商上海拓界生物醫藥科技有限公司 | 一種ｄｓｒｎａ、其應用及製備方法 |
| TW202345865A (zh) * | 2022-01-24 | 2023-12-01 | 大陸商上海舶望製藥有限公司 | 抑制LPA(Apo(a))蛋白表達的組合物和方法 |
| EP4471140A1 (en) | 2022-01-30 | 2024-12-04 | Rona Bioscience, Limited | Targeting ligand containing n-acetylgalactosamine |
| WO2023241591A1 (zh) | 2022-06-14 | 2023-12-21 | 大睿生物医药科技(上海)有限公司 | 调控PCSK9基因活性的siRNA分子 |
| JP2025520796A (ja) * | 2022-06-27 | 2025-07-03 | 大睿生物 | アポリポタンパク質Ｃ３発現を阻害するｓｉＲＮＡ |
| IL317824A (en) * | 2022-07-11 | 2025-02-01 | Sanegene Bio Usa Inc | Ribose derivatives modified at the '2' position and methods of use |
| KR20250043473A (ko) * | 2022-07-27 | 2025-03-28 | 이-테라퓨틱스 피엘씨 | 핵산 화합물 |
| WO2024023256A1 (en) * | 2022-07-27 | 2024-02-01 | E-Therapeutics Plc | Nucleic acid compounds |
| KR20250043472A (ko) * | 2022-07-27 | 2025-03-28 | 이-테라퓨틱스 피엘씨 | 핵산 화합물 |
| CN121271867A (zh) * | 2022-08-05 | 2026-01-06 | 厦门甘宝利生物医药有限公司 | 一种抑制apoc3基因表达的rna抑制剂及其应用 |
| WO2024032680A1 (zh) * | 2022-08-11 | 2024-02-15 | 益杰立科(上海)生物科技有限公司 | 一种表观编辑靶点的方法及用途 |
| AU2024218976A1 (en) * | 2023-02-06 | 2025-09-11 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2024165571A2 (en) * | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2024188173A1 (zh) * | 2023-03-10 | 2024-09-19 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及其用途 |
| WO2025007961A1 (zh) | 2023-07-06 | 2025-01-09 | 大睿生物 | 调控AGT表达的dsRNA分子 |
| KR20260089666A (ko) | 2023-09-14 | 2026-06-15 | 아이오니스 파마수티컬즈, 인코포레이티드 | Apociii 발현을 감소시키기 위한 화합물 및 방법 |
| CN120344664A (zh) * | 2023-10-27 | 2025-07-18 | 北京安龙生物医药有限公司 | 靶向脂蛋白a的寡核苷酸及其用途 |
| WO2025125576A2 (en) * | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4686757A1 (en) * | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibitors of expression and/or function |
| AU2024408289A1 (en) * | 2023-12-22 | 2026-08-06 | Tangram Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025184301A1 (en) * | 2024-02-29 | 2025-09-04 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for dual inhibition of expression of apolipoprotein c-iii (apoc3) and proprotein convertase subtilisin kexin 9 (pcsk9), compositions thereof, and methods of use |
| WO2025237176A1 (zh) * | 2024-05-11 | 2025-11-20 | 深圳信立泰药业股份有限公司 | 用于抑制GPR75基因表达的RNAi剂及其制备方法和用途 |
| WO2026049536A1 (en) * | 2024-08-30 | 2026-03-05 | Olix Pharmaceuticals, Inc. | RNAi AGENT TARGETING APOC3 GENE AND USE THEREOF |
| WO2026139009A1 (zh) * | 2024-12-27 | 2026-07-02 | 成都倍特锐玛生物医药科技有限公司 | RNAi组合物及其应用 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5030453A (en) | 1983-03-24 | 1991-07-09 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
| NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US6977244B2 (en) | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| US5891467A (en) | 1997-01-31 | 1999-04-06 | Depotech Corporation | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
| AU776150B2 (en) | 1999-01-28 | 2004-08-26 | Medical College Of Georgia Research Institute, Inc. | Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| WO2000053722A2 (en) | 1999-03-10 | 2000-09-14 | Phogen Limited | Delivery of nucleic acids and proteins to cells |
| JP2003526367A (ja) | 2000-03-16 | 2003-09-09 | ジェネティカ インコーポレイテッド | Ｒｎａ干渉の方法とｒｎａ干渉組成物 |
| US6680068B2 (en) | 2000-07-06 | 2004-01-20 | The General Hospital Corporation | Drug delivery formulations and targeting |
| CN100523215C (zh) | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | 介导rna干涉的小rna分子 |
| WO2002100435A1 (en) | 2001-06-11 | 2002-12-19 | Centre Hospitalier Universitaire De Montreal | Compositions and methods for enhancing nucleic acid transfer into cells |
| WO2003015757A1 (en) | 2001-08-16 | 2003-02-27 | The Trustees Of The University Of Pennsylvania | Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| EP1658304A4 (en) | 2002-09-28 | 2009-01-14 | Massachusetts Inst Technology | THERAPY ANTIGRIPPALE |
| EP2305813A3 (en) | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| WO2004048545A2 (en) | 2002-11-26 | 2004-06-10 | University Of Massachusetts | DELIVERY OF siRNAs______________________________________________ |
| US20040208921A1 (en) | 2003-01-14 | 2004-10-21 | Ho Rodney J. Y. | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues |
| US7598227B2 (en) * | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
| AU2004257373B2 (en) | 2003-07-16 | 2011-03-24 | Arbutus Biopharma Corporation | Lipid encapsulated interfering RNA |
| CN1845993B (zh) | 2003-08-28 | 2010-06-23 | 诺瓦提斯公司 | 具有平端和3＇修饰的干扰rna双链体 |
| CA2566286A1 (en) | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same |
| EP1948674A4 (en) | 2005-11-02 | 2009-02-04 | Protiva Biotherapeutics Inc | MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF |
| ES2556128T3 (es) | 2006-03-23 | 2016-01-13 | Roche Innovation Center Copenhagen A/S | ARN interfiriente pequeño internamente segmentado |
| GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
| CN101500548A (zh) | 2006-08-18 | 2009-08-05 | 弗·哈夫曼-拉罗切有限公司 | 用于体内递送多核苷酸的多缀合物 |
| NZ580712A (en) | 2007-05-22 | 2011-12-22 | Marina Biotech Inc | Hydroxymethyl substituted rna oligonucleotides and rna complexes containing acyclic monomers |
| US7615374B2 (en) | 2007-09-25 | 2009-11-10 | Wisconsin Alumni Research Foundation | Generation of clonal mesenchymal progenitors and mesenchymal stem cell lines under serum-free conditions |
| US9006191B2 (en) | 2007-12-27 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Silencing of polo-like kinase expression using interfering RNA |
| US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| EP2405921A4 (en) * | 2009-01-26 | 2013-05-22 | Protiva Biotherapeutics Inc | COMPOSITIONS AND METHODS FOR VAPORING APOLIPOPROTIEN C-III EXPRESSION |
| WO2011076807A2 (en) | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| PH12012501596A1 (en) | 2010-02-24 | 2017-02-03 | Arrowhead Res Corporation | Compositions for targeted delivery of sirna |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| EP2723756B1 (en) | 2011-06-21 | 2020-03-11 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes |
| CA2842039A1 (en) | 2011-08-26 | 2013-03-07 | Arrowhead Research Corporation | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
| MX2014001965A (es) | 2012-04-18 | 2014-03-31 | Arrowhead Res Corp | Polimeros de poli(acrilato) para suministro de acido nucleico in vivo. |
| EP3919620A1 (en) * | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
| WO2014205451A2 (en) * | 2013-06-21 | 2014-12-24 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
| WO2015051366A2 (en) | 2013-10-04 | 2015-04-09 | Novartis Ag | Novel formats for organic compounds for use in rna interference |
| EP3736334A1 (en) | 2014-07-16 | 2020-11-11 | Arrowhead Pharmaceuticals, Inc. | Rnai compositions to treat apoc3-related diseases |
| WO2016081444A1 (en) * | 2014-11-17 | 2016-05-26 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
| US20160272970A1 (en) * | 2015-03-17 | 2016-09-22 | Arrowhead Madison Inc. | RNA Interference Agents |
| JOP20160211B1 (ar) * | 2015-10-01 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| JOP20170057B1 (ar) | 2016-03-07 | 2022-03-14 | Arrowhead Pharmaceuticals Inc | مركبات ترابطية مستهدفة كمركبات علاجية |
| JOP20170056B1 (ar) * | 2016-09-02 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | مركبات ترابطية مستهدفة |
| US11603532B2 (en) * | 2017-06-02 | 2023-03-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| SG11201912178VA (en) * | 2017-09-11 | 2020-01-30 | Arrowhead Pharmaceuticals Inc | Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3) |
-
2018
- 2018-09-10 SG SG11201912178VA patent/SG11201912178VA/en unknown
- 2018-09-10 TN TNP/2020/000039A patent/TN2020000039A1/en unknown
- 2018-09-10 UA UAA202002325A patent/UA130735C2/uk unknown
- 2018-09-10 IL IL273172A patent/IL273172B2/en unknown
- 2018-09-10 MY MYPI2020001153A patent/MY202025A/en unknown
- 2018-09-10 EP EP18853495.2A patent/EP3681516A4/en active Pending
- 2018-09-10 CN CN202410900721.1A patent/CN118879696A/zh active Pending
- 2018-09-10 MX MX2020002648A patent/MX2020002648A/es unknown
- 2018-09-10 CA CA3074303A patent/CA3074303A1/en active Pending
- 2018-09-10 KR KR1020247035695A patent/KR20240161202A/ko active Pending
- 2018-09-10 US US16/126,740 patent/US10597657B2/en active Active
- 2018-09-10 CN CN201880059004.3A patent/CN111107853B/zh active Active
- 2018-09-10 JP JP2020514257A patent/JP7438103B2/ja active Active
- 2018-09-10 PE PE2020000340A patent/PE20201283A1/es unknown
- 2018-09-10 JO JOP/2020/0054A patent/JOP20200054A1/ar unknown
- 2018-09-10 CR CR20200108A patent/CR20200108A/es unknown
- 2018-09-10 BR BR112020002413-9A patent/BR112020002413A2/pt unknown
- 2018-09-10 IL IL324223A patent/IL324223A/en unknown
- 2018-09-10 WO PCT/US2018/050248 patent/WO2019051402A1/en not_active Ceased
- 2018-09-10 KR KR1020207006708A patent/KR102723833B1/ko active Active
- 2018-09-10 AU AU2018329190A patent/AU2018329190B2/en active Active
- 2018-09-11 UY UY0001037871A patent/UY37871A/es active IP Right Grant
- 2018-09-11 TW TW107131910A patent/TWI811238B/zh active
- 2018-09-11 TW TW112125927A patent/TW202415389A/zh unknown
-
2020
- 2020-01-31 US US16/778,188 patent/US11214801B2/en active Active
- 2020-02-13 PH PH12020500332A patent/PH12020500332A1/en unknown
- 2020-03-04 CO CONC2020/0002586A patent/CO2020002586A2/es unknown
- 2020-03-06 MX MX2025015219A patent/MX2025015219A/es unknown
- 2020-03-09 CL CL2020000593A patent/CL2020000593A1/es unknown
- 2020-03-11 EC ECSENADI202017905A patent/ECSP20017905A/es unknown
-
2021
- 2021-02-05 ZA ZA2021/00806A patent/ZA202100806B/en unknown
- 2021-11-18 US US17/529,364 patent/US20220064646A1/en not_active Abandoned
-
2022
- 2022-12-22 US US18/145,218 patent/US12365899B2/en active Active
-
2023
- 2023-03-28 JP JP2023051640A patent/JP2023073358A/ja not_active Withdrawn
-
2024
- 2024-11-13 CL CL2024003470A patent/CL2024003470A1/es unknown
-
2025
- 2025-06-18 US US19/242,305 patent/US20260043025A1/en active Pending
- 2025-11-11 AU AU2025267315A patent/AU2025267315A1/en active Pending
- 2025-12-26 JP JP2025285010A patent/JP2026042850A/ja active Pending
- 2025-12-26 JP JP2025285009A patent/JP2026042849A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534268A5 (enExample) | ||
| TWI811238B (zh) | 用於抑制脂蛋白元C-III(APOC3)表現之RNAi試劑及組合物 | |
| JP2026004402A (ja) | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 | |
| JP2018529732A5 (enExample) | ||
| JP2023519246A5 (enExample) | ||
| CN104994884B (zh) | 对脂蛋白脂肪酶缺乏(lpld)群体中的载脂蛋白c-iii(apociii)表达的调节 | |
| CN104302654A (zh) | 用于调节载脂蛋白(a)表达的方法和组合物 | |
| JP2020526192A5 (enExample) | ||
| JP2023536999A (ja) | Ｂ型肝炎患者のオリゴヌクレオチド処置 | |
| JP7829478B2 (ja) | Ａｐｏｃ３関連疾患および障害の処置のための方法 | |
| JP2017510583A (ja) | 遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的ｕｎａオリゴマー | |
| JP2020537653A5 (enExample) | ||
| WO2026026776A1 (zh) | 抑制APP基因表达的siRNA及其缀合物和应用 | |
| JP2024520522A5 (enExample) | ||
| JP2018511555A (ja) | リポジストロフィー集団におけるアポリポタンパク質Ｃ−ＩＩＩ（ＡｐｏＣＩＩＩ）発現の調節 | |
| JP2023541170A (ja) | Ｚ－ａａｔタンパク質のレベルを低下させる方法 | |
| AU2024345844A1 (en) | Compounds and methods for inhibiting lpa | |
| WO2025064819A1 (en) | Compounds and methods for inhibiting lpa | |
| WO2025064815A1 (en) | Compounds and methods for inhibiting lpa | |
| JP2025513757A5 (enExample) | ||
| CN116670278A (zh) | 用于降低z-aat蛋白水平的方法 | |
| TH2001001206A (th) | RNAi เอเจนท์และองค์ประกอบสำหรับการยับยั้งการแสดงออกของอะโปลิโพโปรตีน C-II (APOC3) | |
| RU2851259C1 (ru) | Способы снижения уровней белка z-aat | |
| NZ763275B2 (en) | Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use | |
| TW202546228A (zh) | 用於抑制胰島素樣生長因子１受體表達的ｒｎａ抑制劑 |